Collegium Pharmaceutical: A Business Growing Into a Price That Has Already Left
The stock is down more than half from its 52-week high. The company just raised its full-year revenue guidance. Both...
Evidence Sheet: Caterpillar (CAT)
The standing BullScope yardsticks for Caterpillar, computed from official filings and refreshed with each new edition.
Evidence Sheet: Visa (V)
The standing BullScope yardsticks for Visa, computed from official filings and refreshed with each new edition.
One drug, one billion dollars, and a clock ticking toward 2030
Harmony Biosciences went public in August 2020 selling a single approved drug to a small population of narcolepsy patients. Six...
ANI Pharmaceuticals: The Stock Fell While the Business Grew. The Gap Invites Scrutiny.
Three years ago, ANI Pharmaceuticals was losing money on nearly every dollar it brought in. Today it is generating real...
Tilray Brands: A Dollar of Sales, Thirteen Cents of Losses, and a Stock Whose Valuation Multiple, If the Filed Revenue Trend Holds, Sits Near Its Decade Low
First, the shape of it Tilray's 10-K for fiscal year 2026 shows record revenue of $915 million and a net...
Evidence Sheet: Pepsico (PEP)
The standing BullScope yardsticks for Pepsico, computed from official filings and refreshed with each new edition.
Vertex: A $10 Billion Bet Lands the Same Week a New Drug Crosses $1 Billion
The gist of it The math shows a business that has grown revenue every year for at least five years,...
Viatris: The Business Is Turning, the Price Tag Already Knows It
Six years ago, Pfizer spun out a division of aging branded drugs, Mylan bolted on its generics empire, and the...
Evidence Sheet: Procter & Gamble (PG)
The standing BullScope yardsticks for Procter & Gamble, computed from official filings and refreshed with each new edition.
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.